Voyageur Pharmaceuticals Expands into Mexican Healthcare Market Through Phalanx Distribution Partnership

Voyageur Pharmaceuticals Ltd. has entered into a non-exclusive distribution and wholesale agreement with PHALANX, Comercializadora e Importadora de Componentes SA DE CV, establishing a strategic partnership to drive market expansion into the Mexican healthcare sector. This agreement follows the signing of a non-binding Letter of Intent announced on June 24, 2025, and represents a mutual commitment between both companies to establish Voyageur's presence in Mexico's medical imaging and contrast media markets.

Under the distribution framework, Phalanx will proceed with registering Voyageur's barium contrast media products with Mexican health regulatory authorities and distribute these products through its established distribution network. Voyageur is fully committed to supporting Phalanx throughout this process, working collaboratively to advance regulatory approval, market access, and commercialization efforts. Sales of Voyageur's barium sulfate contrast media products in Mexico and other Latin American countries will be subject to local regulatory approval processes, with the distributor expected to take the lead in preparing and submitting necessary filings with support from Voyageur's technical and regulatory team.

Phalanx brings significant expertise to this partnership as a leading pharmaceutical distributor with a strong presence in Mexico and key Latin American markets that recognize Canadian regulatory approvals. The company provides comprehensive commercial intelligence and strategic market solutions for businesses entering the region, leveraging deep regulatory expertise, precise supply chain management, and actionable market insights. By combining rigorous market analysis with hands-on operational execution, Phalanx ensures successful product launches, optimized logistics, and sustainable growth while accelerating international expansion and minimizing risk for global companies establishing presence across Latin America.

This partnership represents a key milestone in Voyageur's international growth strategy, further expanding the company's global footprint and supporting access to underserved markets with increasing demand for high-quality contrast media. Brent Willis, CEO of Voyageur, emphasized the significance of this development, stating that it marks a significant step forward in the company's commercialization roadmap and reflects continued commitment to expanding global access to innovative, cost-effective imaging solutions. He noted that Latin America is a critical market in Voyageur's expansion plan, and this partnership lays the groundwork for long-term growth.

Voyageur's broader business strategy involves vertically integrating the barium and iodine contrast markets, with plans to transition into a high-margin domestic manufacturer of radiology drugs. The company owns a 100% interest in the Frances Creek Project, which boasts a rare and exceptional grade mineral suitable for the pharmaceutical marketplace. Voyageur believes this natural resource will replace current synthetic products with higher quality imaging products, positioning the company to become the first vertically integrated entity in the radiology contrast media drug market. Additional information about the company can be found at https://voyageurpharmaceuticals.ca.